Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$3.57
+0.8%
$26.15
$1.09
$597.60
$84.82M0.0351,636 shs5.35 million shs
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$0.94
-0.5%
$0.94
$0.03
$1.03
$5.59M0.542,709 shs2,402 shs
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$4.17
+2.7%
$6.47
$3.55
$100.80
$6.01M0.65281,083 shs37,975 shs
NSPX
Inspyr Therapeutics
$0.00
$0.00
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
0.00%-95.31%-95.80%-99.48%-99.94%
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00%0.00%0.00%0.00%-0.53%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
0.00%-7.11%-30.79%-52.95%-83.18%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
0.5989 of 5 stars
0.03.00.00.02.21.70.0
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
3.3444 of 5 stars
3.55.00.00.01.93.30.0
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.00
HoldN/AN/A
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00
N/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
3.00
Buy$35.00739.33% Upside
NSPX
Inspyr Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NSPX, HCWB, CYCC, and FRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$120.00 ➝ $35.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$40K2,120.58N/AN/A($3.93) per share-0.91
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$10.06M0.56N/AN/A$1.66 per share0.56
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$2.57M2.34N/AN/A($6.08) per share-0.69
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$11.21M-$56.00N/AN/AN/A-3,648.09%-155.99%8/13/2025 (Estimated)
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
-$5.69M-$1.41N/AN/AN/AN/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
-$30.02M-$23.25N/AN/A-1,712.94%N/A-90.09%8/13/2025 (Estimated)
NSPX
Inspyr Therapeutics
-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/A

Latest NSPX, HCWB, CYCC, and FRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A-$0.05N/A-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/AN/AN/AN/AN/A
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/A

Latest NSPX, HCWB, CYCC, and FRTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/28/2025
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$36.004/29/20254/29/20255/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
5.60
5.60
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A
0.07
0.07
NSPX
Inspyr Therapeutics
N/A
0.09
0.09

Institutional Ownership

CompanyInstitutional Ownership
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
23.58%
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
25.04%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
2.96%
NSPX
Inspyr Therapeutics
0.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
1423.76 million737,000Optionable
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
205.97 million5.96 millionNot Optionable
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
401.44 million825,000Not Optionable
NSPX
Inspyr Therapeutics
1543.15 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cyclacel Pharmaceuticals stock logo

Cyclacel Pharmaceuticals NASDAQ:CYCC

$3.57 +0.03 (+0.85%)
Closing price 04:00 PM Eastern
Extended Trading
$3.49 -0.08 (-2.24%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Fresh Tracks Therapeutics stock logo

Fresh Tracks Therapeutics NASDAQ:FRTX

$0.94 -0.01 (-0.53%)
As of 02/28/2025

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

HCW Biologics stock logo

HCW Biologics NASDAQ:HCWB

$4.17 +0.11 (+2.71%)
As of 04:00 PM Eastern

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Inspyr Therapeutics OTCMKTS:NSPX

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.